Rolapitant
- TRADE NAME: Varubi (Tesaro)
- INDICATIONS: Delayed nausea and vomiting from chemotherapy, in combination with dexamethasone and a 5HT3-receptor antagonist
- CLASS: Antiemetic, Neurokinin 1 receptor antagonist
- HALF-LIFE: ~7 days
FDA APPROVAL DATE: 09/01/2015
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:A teratogen in animal studies. Drug usage in pregnant women should be conducted only after necessary studies and approvals from regulatory agencies.
Based on its teratogenic properties in developed chick embryos, it is recommended that rolapitant should be taken only when a valid diagnosis has been established and only at the recommended dose, not at a larger dose or for an extended period of time. Drug usage in pregnant women should be conducted after necessary studies and approvals from regulatory agencies.
(Cureus, 2022 Aug 17;14(8):e28097, doi: 10.7759/cureus.28097)
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of rolapitant in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric